Skip to main content

Oral Abstracts

DOWNLOAD ALL ORAL ABSTRACTS (PDF)

VIEW ORAL ABSTRACT PRESENTATIONS (REGISTERED ATTENDEES ONLY)

Development of a Novel Respiratory Syncytial Virus Controlled Human Infection Model: Phase 1 Study of rRSV A/Maryland/001/11 in Healthy Adult Volunteers
Kawsar R. Talaat, MD
Assistant Professor, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD

Development of Single Dose Vaccines Against Emerging Infectious Diseases, Including COVID-19, Using GV-MVA-VLPTM Vector Platform
Farshad Guirakhoo, PhD
Chief Scientific Officer, GeoVax, Inc., Smyrna, GA

Effectiveness of Cell Culture-Based Inactivated Influenza Vaccine against Medically-Attended, Laboratory-Confirmed Influenza in Northcentral Wisconsin, 2018–2019
Kayla E. Hanson, MPH
Epidemiologist, Marshfield Clinic Research Institute, Marshfield, WI

HBV-24: Immunogenicity and Safety of HEPLISAV-B® in Hemodialysis Patients
Randall N. Hyer, MD, PhD, MPH
Vice President, Clinical Development and Medical Affairs, Dynavax Technologies Corporation, Emeryville, CA

Heat Treatment Exposes a Partially Cleaved 27 Amino Acid Peptide (P27) on the Fusion (F) Protein of Infectious Respiratory Syncytial Virus (RSV)
Wanderson Rezende
Graduate Student, Baylor College of Medicine, Houston, TX

Immune-Engineered Antigen Designed to Harness CD4+ T Cell Memory Improves Protection Against Lethal Avian H7N9 Influenza
Lauren Meyers, PhD
Postdoctoral Research Fellow, EpiVax Inc., Providence, RI

In Vivo Assembly of Nanoparticles Achieved Through Synergy of Structure-Based Protein Engineering and Synthetic DNA Generates Enhanced Adaptive Immunity
Ziyang Xu
MD/PhD Candidate, Graduate Research Student, Wistar Institute, Philadelphia, PA

Multi-Modal Vaccination Targeting Clostridioides difficile Based on a Chromosomally Integrated, Attenuated Salmonella Typhimurium Vector Protects Mice from Challenge
Kaitlin Winter
PhD Candidate, McGill University, Montreal, Quebec, Canada

Safety and Immunogenicity of Coadministration of Meningococcal Type A Vaccine with Typhoid Conjugate Vaccine in Healthy Children 15–23 Months of Age in Burkina Faso
Matthew B. Laurens, MD, MPH
Associate Professor, Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD

Therapeutic Application of a YS1646 Salmonella Typhimurium Vectored Vaccine in Mice Chronically-Infected with Schistosoma mansoni
Adam S. Hassan
PhD Student, McGill University, Montreal, Quebec, Canada

Vaccine Effectiveness Against Influenza-Related Hospitalizations and Serious Respiratory Events During the 2017–2018 Influenza Season: Comparison between Quadrivalent Cell-Based and Egg-Based Influenza Vaccines
Joaquin F. Mould, PhD
Global Pricing & Health Economics Director
Seqirus, Summit, NJ